FCGR2A and Thrombocytopenia: In addition, two combined mutations (L234F and S239C) reduced binding to FcγR in order to minimize ADC aspecific internalization (independent of HER2) in normal tissues mediated by FcγR, thereby reducing the occurrence of side effects such as thrombocytopenia [82].